Reflecting on the groundbreaking research presented at ACTRIMS Forum 2025, we are profoundly inspired by the transformative potential of retinal imaging in revolutionizing multiple sclerosis (MS) care:
Statistical evidence from optical coherence tomography (OCT) studies confirms that MS patients exhibit significantly thinner parafoveal retinal nerve fiber layer, ganglion cell layer, and ganglion cell-inner plexiform layer compared to healthy controls—providing clinicians with quantifiable biomarkers that detect neurodegeneration before conventional MRI reveals changes.
Particularly compelling was data establishing parafoveal ganglion cell layer thickness as the dominant predictor of both optic neuritis occurrence and progressive MS status, offering unprecedented precision in disease trajectory forecasting.
The statistically significant correlation between EDSS clinical disability scores and retinal layer measurements (parafoveal GCL: standardized β, -.472; P<.001 and RNFL thickness: standardized β, .187; P=.021) validates these metrics as robust indicators of overall neurological function.
At JuneBrain, we are translating these scientific advancements into actionable clinical solutions through our wearable, AI-powered OCT device and specialized Reading Center. With OCT now incorporated into the McDonald diagnostic criteria for MS, our technology bridges critical gaps in neurotherapeutic development and monitoring.
We remain committed to our human-centered design approach, ensuring these technological innovations transcend laboratory settings to reach patients wherever they are—eliminating geographic and socioeconomic barriers to specialized care while accelerating clinical trials and real-world evidence generation.
We welcome your thoughts on how retinal biomarkers might transform your approach to MS monitoring and treatment decision-making.
(For reference to the stats: [Practical Neurology])
Comments